Raloxifene as an Adjuvant Treatment of the Negative Symptoms of Schizophrenia in Post-menopausal Women

PHASE3CompletedINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

July 31, 2014

Study Completion Date

July 31, 2014

Conditions
Schizophrenia in Post Menopausal Women
Interventions
DRUG

Raloxifene

The dose of raloxifene hydrochloride administered will be 60 mg/day. Both placebo and the raloxifene will be administered over 6 months. Patients will take one single daily dose administered in the morning. Drug will be given orally in capsule form.

DRUG

Lactosa (placebo arm)

Both placebo and the raloxifene will be administered over 6 months. Patients will take one single daily dose administered in the morning. Drug will be given orally in capsule form.

Trial Locations (3)

43206

Hospital Psiquiàtric Institut Pere Mata, Reus

08208

Corporació Sanitària Parc Taulí, Sabadell

08830

Parc Sanitari Sant Joan de Déu, Sant Boi de Llobregat

All Listed Sponsors
collaborator

Hospital Sant Joan de Deu

OTHER

collaborator

Parc Sanitari Sant Joan de Déu

OTHER

collaborator

Stanley Medical Research Institute

OTHER

lead

Fundació Sant Joan de Déu

OTHER

NCT01573637 - Raloxifene as an Adjuvant Treatment of the Negative Symptoms of Schizophrenia in Post-menopausal Women | Biotech Hunter | Biotech Hunter